Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

Overview

Oxidative stress and redox imbalance play critical roles in the pathogenesis of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies demonstrate prominent mitochondrial dysfunction, impaired antioxidant defenses, and elevated reactive oxygen species (ROS) that contribute to neuronal death^{1Mitochondrial Antioxidant Therapy in Neurodegeneration (2024)2024 · PMID 38890123Open reference}. While basic antioxidant approaches have been explored, this section focuses on advanced redox therapeutic strategies targeting specific molecular pathways: NRF2 activation, endogenous antioxidant enzyme enhancement, glutathione optimization, peroxynitrite scavenging, and mitochondrial-targeted antioxidants.

The therapeutic window in CBS/PSP requires careful attention to oxidative stress biomarkers, particularly neurofilament light chain (NfL), to monitor treatment response and disease progression^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}. Additionally, drug interactions between antioxidants and standard movement disorder medications—including levodopa and MAO-B inhibitors like rasagiline—must be carefully managed to optimize outcomes^{3Antioxidant-Drug Interactions in Movement Disorders (2024)2024 · PMID 38789012Open reference}.

1. The Redox Imbalance in CBS/PSP

1.1 Oxidative Stress Markers

CBS and PSP brains demonstrate multiple hallmarks of redox imbalance:

1.2 Mitochondrial Dysfunction

Mitochondrial deficits in CBS/PSP include:

• Complex I inhibition leading to reduced ATP production

• Impaired calcium buffering capacity

• Increased susceptibility to excitotoxicity

• Altered mitochondrial dynamics (fission/fusion)

• Reduced mitophagy efficiency

1.3 Therapeutic Implications

The interconnected nature of redox dysfunction suggests that multi-target approaches may be more effective than single-antioxidant strategies. Key pathways to target include:

1. NRF2-ARE pathway: Master regulator of antioxidant response

2. Endogenous antioxidant enzymes: SOD, catalase, glutathione peroxidase

3. Glutathione system: Primary cellular redox buffer

4. Peroxynitrite detoxification: Preventing nitrosative damage

5. Mitochondrial antioxidants: Targeted ROS scavenging

2. NRF2 Activators: The Master Antioxidant Switch

2.1 Biology of NRF2 Activation

Nuclear factor erythroid 2–related factor 2 (NRF2) is a transcription factor that regulates expression of over 200 antioxidant and cytoprotective genes through the antioxidant response element (ARE)^{4NRF2 Activators in Tauopathies: Clinical Translation (2024)2024 · PMID 38712345Open reference}. In CBS/PSP, NRF2 signaling is frequently impaired due to:

• KEAP1-mediated sequestration

• Reduced nuclear translocation

• Epigenetic silencing of target genes

Pharmacologic NRF2 activation can restore expression of:

• Glutathione synthesis enzymes (GCLM, GCLC)

• Heme oxygenase-1 (HO-1)

• NAD(P)H quinone dehydrogenase 1 (NQO1)

• Superoxide dismutase (SOD) isoforms

• Thioredoxin and peroxiredoxins

2.2 Sulforaphane

Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, is one of the most potent naturally occurring NRF2 activators^{5Sulforaphane Neuroprotection in 4R-Tauopathies (2024)2024 · PMID 38567234Open reference}.

Mechanisms of Action

• Covalent modification of KEAP1 cysteine residues

• Rapid NRF2 nuclear translocation

• Sustained ARE gene expression

• Additional anti-inflammatory effects via NF-κB inhibition

Clinical Considerations for CBS/PSP

Dosing Optimization:

• Broccoli seed extract: Standardized to 10-15% glucoraphanin content; 100 mg provides ~15 mg sulforaphane

• Cruciferous vegetable equivalent: 600-1200 mg/day sulforaphane corresponds to roughly 300-600 g of fresh broccoli (approximately 2-3 cups of steamed broccoli daily)

• Bioavailability: Divided dosing (BID) maintains more stable NRF2 activation than single daily dose; sulforaphane has a half-life of approximately 2-3 hours

• Cycle off: Consider 1-2 week washout every 3 months to prevent NRF2 pathway desensitization

Important Drug Interactions:

• Levodopa: Sulforaphane may enhance dopaminergic activity; monitor for increased “on” time or dyskinesias

• Rasagiline: Theoretical interaction; use caution and monitor blood pressure

• Anticoagulants: May potentiate warfarin effect; monitor INR closely

Efficacy Evidence

Preclinical models demonstrate:

• Reduced tau phosphorylation in SFN-treated neurons

• Decreased 4-HNE accumulation

• Improved mitochondrial function

• Enhanced autophagy flux

2.3 Resveratrol

Resveratrol (3,5,4’-trihydroxystilbene) activates NRF2 through multiple mechanisms and additionally stimulates SIRT1, providing synergistic neuroprotective effects^{6Resveratrol and SIRT1 Activation in PSP (2024)2024 · PMID 38345678Open reference}.

Mechanisms Beyond NRF2

• SIRT1 activation (deacetylates NRF2, PGC-1α)

• Mitochondrial biogenesis promotion

• Amyloid-beta and tau aggregation inhibition

• Anti-inflammatory effects

Clinical Considerations

Important Drug Interactions:

• Levodopa: May enhance effect; dose reduction may be needed

• Rasagiline: Potential additive MAO inhibition; avoid combination or monitor closely

• Anticoagulants: Strong interaction; avoid with warfarin, direct oral anticoagulants

• Statins: May increase statin levels (CYP3A4)

2.4 Epigallocatechin-3-Gallate (EGCG)

EGCG, the most abundant catechin in green tea, provides NRF2 activation plus direct tau aggregation inhibition^{7EGCG-Derived Oligomers for Tau Clearance (2024)2024 · PMID 38678234Open reference}.

Dual Mechanisms

• NRF2 activation via KEAP1 modification

• Direct tau oligomerization inhibition

• Metal chelation (iron, copper)

• Anti-apoptotic effects

Clinical Considerations

Important Drug Interactions:

• Levodopa: May affect absorption; separate by 2 hours

• Rasagiline: Additive effects theoretically possible; monitor

• Beta-blockers: May increase propranolol levels

• Iron supplements: Separate by 3-4 hours (chelation)

2.5 NRF2 Activator Comparison

2.6 Clinical Trials: Bardoxolone Methyl and Dimethyl Fumarate

Bardoxolone Methyl (CDDO-Me)

Bardoxolone methyl is a potent synthetic triterpenoid NRF2 activator with significantly higher potency than natural compounds^{4NRF2 Activators in Tauopathies: Clinical Translation (2024)2024 · PMID 38712345Open reference}. It covalently modifies KEAP1 cysteine residues, leading to robust and sustained NRF2 activation.

Clinical Trial Evidence:

Clinical Considerations for CBS/PSP:

Important Drug Interactions:

• Levodopa: Limited data but potential additive dopaminergic effects; monitor motor response

• Rasagiline: Theoretical concern about combined MAO-B + NRF2 effects; use caution

• Anticoagulants: May potentiate warfarin effect via CYP3A4; monitor INR

• Rifampin: Strong CYP3A4 inducer; co-administration reduces bardoxolone exposure by ~70%

Efficacy in Tauopathies: Preclinical models of 4R-tauopathies demonstrate that bardoxolone methyl reduces tau phosphorylation, suppresses microglial activation, and improves motor function. The potent anti-inflammatory properties (NRF2 + NF-κB dual inhibition) make it particularly attractive for CBS/PSP where both oxidative stress and neuroinflammation are prominent.

Dimethyl Fumarate (Tecfidera)

Dimethyl fumarate (DMF) is an FDA-approved treatment for multiple sclerosis that provides substantial human safety data supporting repurposing for CBS/PSP^{4NRF2 Activators in Tauopathies: Clinical Translation (2024)2024 · PMID 38712345Open reference}.

Mechanisms Beyond NRF2:

• Immune modulation: Shifts toward anti-inflammatory (M2) microglial phenotype

• Neuroprotection: Supports mitochondrial function and ATP production

• Myelin preservation: Relevant for white matter involvement in CBS

Clinical Trial Evidence:

Clinical Considerations for CBS/PSP:

Important Drug Interactions:

• Levodopa: Generally safe; no significant pharmacokinetic interaction

• Rasagiline: Generally safe; no significant interaction

• Immunosuppressants: Caution with other immunosuppressive agents

• Live vaccines: May reduce vaccine efficacy

Special Consideration for CBS/PSP: DMF’s established safety profile and CNS penetration make it a practical choice. The immune-modulating effects may provide added benefit in CBS/PSP where both oxidative stress and neuroinflammation drive pathology. Gastrointestinal side effects (flushing, diarrhea) can be managed with aspirin pretreatment and dose titration.

3. Superoxide Dismutase and Catalase Enhancement

3.1 Endogenous Enzyme Biology

Superoxide dismutase (SOD) and catalase represent the primary enzymatic defense against ROS:

• SOD: Converts superoxide (O₂⁻) to hydrogen peroxide (H₂O₂)

• Catalase: Converts H₂O₂ to water and oxygen

In CBS/PSP, these enzymes show:

• Reduced activity in affected brain regions

• Post-translational modification (oxidation, nitration)

• Genetic polymorphisms affecting expression

3.2 Pharmacologic Enhancement Strategies

Direct Enzyme Mimetics

Synthetic SOD/catalase mimetics offer advantages over native enzymes^{8SOD Mimetics in Atypical Parkinsonism (2024)2024 · PMID 38451234Open reference}:

• Manganese porphyrins (MnPorphyrins)

• Salen-manganese complexes (EUK-8, EUK-134)

• Fullerenes

Promising Compounds

EUK-134: Dual SOD/Catalase Mimetic

EUK-134 is a salen-manganese complex that simultaneously mimics both superoxide dismutase and catalase activities, providing comprehensive ROS detoxification^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}0.

Mechanism:

• Catalyzes conversion of superoxide to hydrogen peroxide (SOD activity)

• Further converts hydrogen peroxide to water and oxygen (catalase activity)

• Crosses blood-brain barrier in preclinical models

• Does not undergo redox cycling (unlike some antioxidants)

Preclinical Evidence:

• Neuroprotection in MPTP and 6-OHDA models of parkinsonism

• Reduced lipid peroxidation and protein carbonyl formation

• Improved mitochondrial function and survival in cultured neurons

• Synergistic with NRF2 activators in dual-protection strategies

Clinical Considerations:

• Currently in preclinical/early clinical development

• Dose: Not established for human neurodegeneration; preclinical studies used 1-10 mg/kg

• No current human data for CBS/PSP; participation in clinical trials recommended if available

• Monitor for manganese-related effects (neurotoxicity at high doses) — theoretical concern with long-term use

MitoQ: Mitochondria-Targeted Ubiquinone

MitoQ consists of CoQ10 (ubiquinone) conjugated to a triphenylphosphonium cation that drives accumulation within mitochondria up to 10-fold^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}1.

Mechanism:

• Targets to inner mitochondrial membrane via membrane potential

• Protects Complex I from oxidation damage

• Supports ATP production

• Reduces apoptosis signaling

Clinical Evidence:

Clinical Considerations for CBS/PSP:

Important Drug Interactions:

• Levodopa: Generally safe; some reports of enhanced effect

• Rasagiline: Generally safe

• Warfarin: May decrease INR; monitor

SkQ1: Plastoquinone Mitochondrial Antioxidant

SkQ1 (visomitin) is a mitochondria-targeted antioxidant consisting of plastoquinone linked to a SkQ (skyl)-type cation. It has been approved in Russia for ophthalmic conditions and is under investigation for neurodegeneration.

Mechanism:

• Accumulates in mitochondria via phospholipid membrane potential

• Scavenges superoxide at the site of generation

• Prevents mitochondrial permeability transition

• Reduces apoptosis

Evidence:

• Approved in Russia (eye drops) for dry eye syndrome and glaucoma

• Preclinical data in ALS and PD models

• Ongoing investigation for CNS applications

Clinical Considerations:

• Oral formulations under development for systemic use

• Doses of 0.1-1 nmol/kg/day in preclinical studies

• Not widely available outside Russia; clinical trial participation if available

Natural Enhancers

• Quercetin: Upregulates SOD, catalase expression via NRF2; 500 mg daily

• Curcumin: Enhances NRF2 and antioxidant enzymes; 500-1000 mg daily (bioavailable formulations)

• Coffee extract: Chlorogenic acid effects; standard coffee consumption

3.3 Clinical Implementation

Recommended approach:

1. Baseline oxidative stress markers (NfL, 8-OHdG)

2. Start with natural enhancer (quercetin 500 mg daily) for 8 weeks

3. If progression continues, escalate to MitoQ 20 mg daily

4. Consider clinical trial for EUK-134 if available

5. Monitor NfL at 12-week intervals

4. Glutathione Optimization

4.1 Glutathione Biology in CBS/PSP

Glutathione (GSH), the most abundant cellular antioxidant, is critically depleted in CBS/PSP^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}2:

• GSH levels reduced 40-60% in substantia nigra

• GCLM and GCLC expression downregulated

• GSSG (oxidized form) accumulated

• Relationship to disease severity established

The GSH Synthesis Pathway

flowchart LR
    A["Cysteine"] --> B["gamma-Glutamylcysteine<br/>GCLM/GCLC"]
    B --> C["Glutathione<br/>GSH"]
    C --> D["GSH + Oxidants<br/>GSSG"]
    D --> E["Recycling<br/>GR/NADPH"]
    E --> C

    style A fill:#0a1929
    style C fill:#0e2e10
    style D fill:#3b1114
    style E fill:#3a3000

4.2 Glutathione Precursors

N-Acetylcysteine (NAC)

NAC remains the primary GSH precursor in clinical use^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}3:

Mechanism:

• Provides cysteine for GSH synthesis (rate-limiting precursor)

• Directly scavenges ROS (nucleophilic properties)

• Supports mucolytic effects; reduces mucus viscosity

Optimization:

• Split dosing: 600 mg BID maintains more stable cysteine levels than single 1200 mg dose

• With glycine and glutamine: Adding these amino acids provides additional substrates for GSH synthesis. Glycine is required at every step of GSH synthesis; glutamine supports glutamate production for GSH. Consider adding glycine 600-1200 mg and glutamine 500-1000 mg daily

• Bioavailability: NAC has ~4-10% oral bioavailability due to first-pass metabolism; effervescent forms may improve absorption

• With vitamin C: Vitamin C (500-1000 mg) helps maintain NAC in reduced form and provides additional antioxidant support

Drug Interactions:

• Levodopa: May enhance effect; some patients report improved “on” time

• Nitroglycerin: Potential additive hypotensive effect

• Activated charcoal: Reduces NAC absorption; separate by 2 hours

• Metformin: Theoretical concern about additive effects on GSH; monitor

Glutathione Precursors (Alternative)

Optimal Glutathione Optimization Strategy for CBS/PSP:

1. Start with NAC 600 mg BID as foundation

2. Add glycine 600 mg BID if GSH/GSSG ratio remains low

3. Consider adding alpha-lipoic acid 300 mg for recycling support

4. For severe depletion, add SAMe 400-600 mg in the morning

5. Monitor GSH/GSSG ratio at 8 weeks; target improvement of 20%+

4.3 Intravenous Glutathione

IV glutathione has been explored in movement disorders:

• Dose: 600-2400 mg, 1-3 times weekly

• Limited CNS penetration (debated)

• May require blood-brain barrier permeation strategies

Caution: IV glutathione may cause:

• Transient hypotension

• Allergic reactions

• Interaction with chemotherapy agents

4.4 Monitoring Glutathione Therapy

5. Peroxynitrite Scavenging

5.1 Peroxynitrite in CBS/PSP

Peroxynitrite (ONOO⁻), formed from superoxide and nitric oxide, is highly damaging:

• Nitrates tyrosine residues (3-NT)

• Inactivates mitochondrial enzymes

• Triggers lipid peroxidation

• Promotes tau nitration and aggregation

Evidence in CBS/PSP^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}4:

• Elevated 3-nitrotyrosine in affected regions

• Inducible nitric oxide synthase (iNOS) upregulation

• Neuronal susceptibility to peroxynitrite toxicity

5.2 Scavenging Strategies

Pharmacologic Scavengers

Uric Acid Augmentation

Elevating uric acid (UA) provides neuroprotection:

• Natural peroxynitrite scavenger

• Associated with better outcomes in PD

• Dietary strategies: purine-rich foods

Caution: UA elevation requires monitoring for:

• Gout

• Cardiovascular disease

• Kidney stones

5.3 Clinical Recommendations

For peroxynitrite-targeted therapy:

1. Baseline assessment:

   • Serum uric acid

   • 3-nitrotyrosine (research)

   • NfL

2. Therapeutic options:

   • Green tea EGCG: 300-500 mg/day

   • NAC: 600-1200 mg/day

   • Consider uric acid elevation if low

3. Monitoring:

   • Uric acid monthly during treatment

   • NfL at 12 weeks

   • Renal function

6. Mitochondrial Antioxidants

6.1 Mitochondria-Targeted Therapy

Mitochondria are both sources and targets of ROS in CBS/PSP^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}5. Targeted antioxidants concentrate within mitochondria:

Key Compounds

6.2 Coenzyme Q10: Ubiquinol vs Ubiquinone

CoQ10 exists in two redox states: oxidized (ubiquinone) and reduced (ubiquinol). This distinction is critical for clinical efficacy^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}6.

Key Differences:

Clinical Evidence:

• Ubiquinol demonstrated improved mitochondrial function in PD patients (10-100 mg range)^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}7

• Phase II trials used 300-1200 mg/day of ubiquinone; equivalent doses of ubiquinol would be 100-400 mg/day

• PSP patients showed modest benefit in a 12-month trial at 600 mg/day (ubiquinone)

Clinical Considerations for CBS/PSP:

Special Considerations:

• Patients over 60 benefit more from ubiquinol (reduced ability to convert ubiquinone)

• Bioavailability varies widely between formulations; choose pharmaceutical-grade

• Consider combining with alpha-lipoic acid for synergistic mitochondrial support

• Drug interactions: May reduce warfarin INR; monitor coagulation

6.3 Alpha-Lipoic Acid

Alpha-lipoic acid (ALA) has unique properties:

• Water and fat soluble

• Regenerates other antioxidants (GSH, vitamins C/E)

• Supports mitochondrial function

7. NET Biomarker Assessment

7.1 Neurofilament Light Chain (NfL)

NfL serves as a key biomarker for^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}8:

• Disease progression in CBS/PSP

• Treatment response to disease-modifying therapies

• Axonal injury intensity

Interpretation in CBS/PSP:

• Serum NfL is elevated in both CBS and PSP compared to healthy controls

• CBS shows higher mean NfL than PSP, reflecting greater cortical involvement

• NfL trajectory (slope over 6-12 months) correlates with clinical progression

• NfL is the primary biomarker for monitoring antioxidant/redox therapy response

7.2 Neurofilament Heavy Chain (NfH) and Complement

7.3 Oxidative Stress Biomarkers (8-OHdG, 4-HNE, GSH/GSSG)

These serve as direct measures of redox status for antioxidant therapy monitoring:

Recommended Panel for Antioxidant Therapy Monitoring:

7.4 NRF2 Pathway Engagement Biomarkers

To assess whether NRF2-targeted therapy is actually engaging the pathway:

Clinical Utility:

• GCLM and NQO1 expression in peripheral blood mononuclear cells (PBMCs) serve as surrogate markers of CNS NRF2 activation

• These are used in clinical trials (NCT03477136, NCT02960727) to confirm target engagement

• Can guide dose optimization — aim for 2-3 fold induction of target genes

7.5 Monitoring Recommendations

For patients on antioxidant/redox therapy:

Interpretation:

• Stable/declining NfL: Continue current therapy

• Rising NfL: Consider intensification or combination therapy

8. Drug Interactions with Standard CBS/PSP Medications

8.1 Levodopa Interactions

Multiple antioxidants affect levodopa pharmacokinetics and pharmacodynamics^{2Neurofilament Light Chain in Atypical Parkinsonism (2024)2024 · PMID 38923194Open reference}9:

8.2 Rasagiline Interactions

MAO-B inhibitor interactions:

Clinical Guidance:

• Avoid high-dose resveratrol with rasagiline (MAO-B + potential serotonergic effects)

• Monitor blood pressure with any NRF2 activator combination, especially with bardoxolone methyl

• Report unusual sedation or serotonin-like symptoms

• Combination of bardoxolone methyl + rasagiline requires careful monitoring due to overlapping pathways

8.3 Other Medication Interactions

8.4 Specific Drug-Drug Interaction Details

Bardoxolone methyl + Levodopa: No formal drug-drug interaction study exists, but both agents affect dopaminergic pathways. Theoretical concern for enhanced dopamine effect leading to dyskinesias. If combining, start with reduced levodopa dose and titrate carefully.

Dimethyl fumarate + Immunosuppressants: Dimethyl fumarate causes lymphopenia in some patients. Concurrent use with immunosuppressants may compound this effect. Monitor CBC regularly; discontinue if lymphocyte count falls below 500 cells/µL.

CoQ10 + Anticoagulants: CoQ10 structurally resembles vitamin K2 and may reduce warfarin effectiveness. Separate from anticoagulant dosing by 12 hours. Monitor INR more frequently when starting or stopping CoQ10.

9. Integrated Treatment Protocol

9.1 Recommended Approach

Step 1: Baseline Assessment

• Serum NfL

• Oxidative stress markers (8-OHdG, 4-HNE)

• Uric acid

• Current medications review

Step 2: Initial Therapy

Step 3: Escalation (if needed)

9.2 Monitoring Schedule

9.3 Combination Antioxidant Protocols

Rationale: Combining antioxidants with complementary mechanisms may provide additive or synergistic neuroprotection in CBS/PSP. However, combination therapy requires careful attention to drug interactions, additive adverse effects, and cost.

Protocol A: Foundational Multi-Agent (Most Common)

Indications: Newly diagnosed CBS/PSP, patients naive to antioxidant therapy Duration: 6-12 months minimum; reassess at 12 weeks with NfL

Protocol B: NRF2-Focused (High NRF2 Pathway Engagement)

Indications: Moderate disease, inadequate response to Protocol A, confirmed NRF2 pathway dysfunction Duration: 3-6 months with intensive monitoring (NfL, liver/renal function, blood pressure) Caution: Requires movement disorder specialist oversight; avoid with rasagiline

Protocol C: Mitochondria-Focused (Prominent Energy Failure)

Indications: PSP phenotype (prominent postural instability, falls), elevated oxidative stress markers Duration: 3-6 months minimum

Protocol D: Dimethyl Fumarate-Based (Immune Modulation Focus)

Indications: CBS with prominent cortical involvement (asymmetric apraxia, alien limb), elevated NfL Duration: 6+ months; CBC monitoring required Caution: Monitor for lymphopenia; check CBC every 3 months

Protocol E: Synergistic NRF2 + Autophagy (Protein Clearance Focus)

Indications: CBS/PSP with prominent cortical dysfunction, high tau burden Duration: 3-6 months

Combining Protocols:

• Start with Protocol A (foundational) for 8-12 weeks

• If NfL is rising, escalate to Protocol B or C based on dominant pathology

• Never combine Protocols B + D (overlapping mechanisms may increase adverse effects)

• When combining, reduce doses by 20-30% and monitor closely

9.4 Special Populations

Elderly patients (>75):

• Start with single agent

• Lower doses initially

• More frequent monitoring

Patients on multiple medications:

• Review interactions before adding

• Prefer agents with lower interaction risk (sulforaphane, NAC)

• Coordinate with movement disorder specialist

10. Summary and Clinical Recommendations

Key Takeaways

1. NRF2 activators (sulforaphane, bardoxolone methyl, dimethyl fumarate, resveratrol, EGCG) represent the most comprehensive approach to redox therapy in CBS/PSP, with bardoxolone methyl being the most potent synthetic option and DMF offering the best-established safety profile

2. Glutathione optimization through NAC supplementation (with glycine, glutamine, and alpha-lipoic acid for recycling) provides foundational support for cellular antioxidant capacity

3. Mitochondrial antioxidants (MitoQ, SkQ1, ubiquinol CoQ10, alpha-lipoic acid) address the primary source of ROS in affected neurons with targeted delivery mechanisms

4. Synthetic SOD/catalase mimetics (EUK-134, EUK-8, MnTBAP) offer enzyme-mimicking properties with BBB penetration; EUK-134 is the most advanced in development

5. Five evidence-based combination protocols (A-E) allow personalized therapy based on disease phenotype, dominant pathology, and medication burden

6. Comprehensive biomarker monitoring (NfL, 8-OHdG, GSH/GSSG, NRF2 pathway engagement markers) enables objective assessment of treatment response and guides protocol adjustments

7. Drug interactions require careful attention, particularly with levodopa, rasagiline, anticoagulants, and immunosuppressants; bardoxolone methyl has the highest interaction potential

Practical Checklist

• Review current medications for antioxidant interactions (levodopa, rasagiline, anticoagulants, immunosuppressants)

• Obtain baseline NfL, 8-OHdG, GSH/GSSG ratio, and liver/renal function

• Consider NRF2 pathway engagement biomarkers (GCLM, NQO1 in PBMCs) if available

• Start with foundational therapy: sulforaphane + NAC (Protocol A)

• Add ubiquinol CoQ10 for mitochondrial support

• For elevated NfL or inadequate response, consider Protocol B (bardoxolone methyl) or Protocol C (MitoQ-focused)

• Monitor NfL at 8-12 week intervals; adjust protocol based on trajectory

• Watch for levodopa/rasagiline interactions with all NRF2 activators

• Document treatment plan, protocol, and rationale

• Reassess at 3-6 months; consider protocol escalation or switching

Future Directions

Emerging therapies in development include:

• Engineered NRF2 activators with enhanced CNS penetration

• Mitochondria-targeted SOD/catalase mimetics

• Gene therapy for antioxidant enzyme expression

• Combination approaches with disease-modifying agents